Credit Suisse analyst Martin Auster maintained a Hold rating on Ultragenyx (RARE) yesterday and set a price target of $59. The company’s shares closed yesterday at $51.29.
According to TipRanks.com, Auster has 0 stars on 0-5 star ranking scale with an average return of -13.6% and a 7.1% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Alexion Pharmaceuticals, and Intellia Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $70.20 average price target, which is a 36.9% upside from current levels. In a report issued on November 8, Citigroup also upgraded the stock to Hold with a $54 price target.
.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $87.31 million. In comparison, last year the company had a GAAP net loss of $79.23 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. Last month, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
